Skip to main content
SpringerLink
Log in

Trastuzumab

  • Chapter
  • First Online:
Adjuvant Therapy for Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 151))

Systemic adjuvant therapy is regularly recommended for patients diagnosed with invasive breast cancer based on risk of recurrence and likelihood of benefit from therapy. Progress in molecular biology has resulted in the identification and improved understanding of molecular markers that may have prognostic and predictive value for patients with breast cancer. HER2 (human epidermal growth factor receptor 2) is one of the best characterized of these markers and now plays a critical role in patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63–9.

    Article  PubMed  CAS  Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.

    Article  PubMed  CAS  Google Scholar 

  3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.

    Article  PubMed  CAS  Google Scholar 

  4. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972–7.

    Article  PubMed  CAS  Google Scholar 

  5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.

    Article  PubMed  CAS  Google Scholar 

  6. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8(1):103–12.

    PubMed  CAS  Google Scholar 

  7. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330(18):1260–6.

    Article  PubMed  CAS  Google Scholar 

  8. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361–70.

    Article  PubMed  CAS  Google Scholar 

  9. Thomas E, Berner G. Prognostic and predictive implications of HER2 status for breast cancer patients. Eur J Oncol Nursing. 2000;4(Suppl1):10–7.

    Article  CAS  Google Scholar 

  10. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151(6):1523–30.

    PubMed  CAS  Google Scholar 

  11. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001;28(5 Suppl 16):4–11.

    Article  PubMed  CAS  Google Scholar 

  12. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253–68.

    Article  PubMed  CAS  Google Scholar 

  13. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 Study Group. J Clin Oncol. 2005;23(19):4265–74.

    Article  PubMed  CAS  Google Scholar 

  14. Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat. 2006;100(Suppl 1):S103.

    Article  Google Scholar 

  15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  PubMed  CAS  Google Scholar 

  16. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162–71.

    Article  PubMed  CAS  Google Scholar 

  17. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.

    PubMed  CAS  Google Scholar 

  18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.

    Article  PubMed  CAS  Google Scholar 

  19. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.

    Article  PubMed  CAS  Google Scholar 

  20. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Article  PubMed  CAS  Google Scholar 

  22. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(18S):6S.

    Google Scholar 

  23. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369(9555):29–36.

    Article  PubMed  CAS  Google Scholar 

  24. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94(Suppl 1):S5.

    Google Scholar 

  25. Clinical Trials website. Maintained by the United States National Institutes of Health: National Library of Medicine. National Library of Medicine. 2007. Available at http://www.clinicaltrials.gov. Accessed October 2007.

  26. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739–49.

    Article  PubMed  CAS  Google Scholar 

  27. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004;96(10):759–69.

    Article  PubMed  CAS  Google Scholar 

  28. Perez EA, Suman VJ, Rowland KM. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005;6:425–32.

    Article  PubMed  CAS  Google Scholar 

  29. Robert N, Loesch D, Lindquist D. A randomized, phase II trial of weekly paclitaxel vs. weekly paclitaxel + carboplatin for first-line metastatic breast cancer. Breast Cancer Res Treat. 2003;77:534.

    Google Scholar 

  30. Robert N, Leyland-Jones B, Asmar L, et al. Randomised phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Proc Am Soc Clin Oncol. 2004;23:20.

    Google Scholar 

  31. Rowland KM, Suman VJ, Ingle JN, et al. NCCTG 98-32-52: Randomized phase II trial of weekly versus every 3-week administration of paclitaxel, Carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:8.

    Google Scholar 

  32. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without wrastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231–38.

    Google Scholar 

  33. Rastogi P, Jeong J, Geyer, et al. CE. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol. 2007;25(18S):513.

    Google Scholar 

  34. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.

    Article  PubMed  CAS  Google Scholar 

  35. Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Part I of II. Vol 23, No. 16S (June 1 Suppl), 2005:556.

    Google Scholar 

  36. Slamon D, Eiermann W, Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: Second interim efficacy analysis. Breast Cancer Res Treat. 2006;100(Suppl 1):52.

    Google Scholar 

  37. Halyard MY, Pisansky TM, Solin LJ, et al. Adjuvant radiotherapy and trastuzumab in stage I–IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol. 2006;24(18S):8S.

    Google Scholar 

  38. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–20.

    Article  PubMed  CAS  Google Scholar 

  39. Sledge GW, O'Neill A, Thor AD. Adjuvant trastuzumab: Long-term results of E2198. Breast Cancer Res Treat. 2006;100(Suppl 1):S106.

    Google Scholar 

  40. NCCN Clinical Practice Guidelines in Oncology: Breast cancer. National Comprehensive Cancer Network 2007. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed May 2007.

  41. Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum. 2006;33(2):265–72.

    Article  PubMed  Google Scholar 

  42. Paik S, Kim C, Jeong J. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol. 2007;25(18S):511.

    Google Scholar 

  43. Garrison L, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Am J Clin Oncol. 2007;110:489–98.

    CAS  Google Scholar 

  44. Kurian A, Thompson R, Gaw A, Arai S, Ortiz R, Garber A. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634–41.

    Article  PubMed  CAS  Google Scholar 

  45. Liberato N, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625–33.

    Article  PubMed  Google Scholar 

  46. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2006;24(19):3032–8.

    Article  PubMed  Google Scholar 

  47. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852–4.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Funding partially provided by the Breast Cancer Research Foundation.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA

    Edith A. Perez MD

  2. Division of Hematology/Oncology and Breast Clinic, Mayo Clinic, Jacksonville, Florida, USA

    Frances M. Palmieri RN, MSN, OCN & Shelly M. Brock

Authors
  1. Edith A. Perez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frances M. Palmieri RN, MSN, OCN
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shelly M. Brock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edith A. Perez MD .

Editor information

Editors and Affiliations

  1. Inselspital, Univ. Bern, Bern, 3010, Switzerland

    Monica Castiglione

  2. Inst. Jules Bordet, Universite Libre Bruxelles, Bd. de Waterloo 125, Bruxelles, 1000, Belgium

    Martine J. Piccart

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Perez, E.A., Palmieri, F.M., Brock, S.M. (2009). Trastuzumab. In: Castiglione, M., Piccart, M. (eds) Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-75115-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75115-3_12

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-75114-6

  • Online ISBN: 978-0-387-75115-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation